Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure and liver-based metabolic defects. Current challenges in this field include a limited cell source, reduced cell viability following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. As a result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial cells and mesenchymal stem/stromal cells (MSCs) can be used to generate induced hepatocyte like cells (HLC) with each technique exhibiting advantages and disadvantages. HLCs may have comparable function to primary human hepatocytes and could offer patient-specific treatment. However, long-term functionality of transplanted HLCs and the potential oncogenic risks of using stem cells have yet to be established. The immunomodulatory effects of MSCs are promising, and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. Here, we review the current status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver regeneration. We also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving the phenotype of several liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotubular Highways for Intercellular Organelle Transport
Rustom, A., Saffrich, R., Markovic, I., Walther, P., & Gerdes, H.-H. (2004) · Science · doi:10.1126/science.1093133 · Cited by 2,038
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Bernal, W., & Wendon, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208937 · Cited by 1,169
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Bipotential Adult Liver Progenitors Are Derived from Chronically Injured Mature Hepatocytes
Tarlow, B. D., Pelz, C., Naugler, W. E., Wakefield, L., Wilson, E. M., Finegold, M. J., & Grompe, M. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.09.008 · Cited by 533 · cited 1×
“Chemically induced liver progenitors Recently, it has been shown that mature hepatocytes convert to HLCs during chronic liver injury [67].”
BackgroundHuman hepatocyte transplantation: current experience and future challenges
Dhawan, A., Puppi, J., Hughes, R. D., & Mitry, R. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.44 · Cited by 362 · cited 10×
“ALF Acute liver failure BMM Bone marrow-derived macrophages BMP4 Bone morphogenetic protein 4 CN-1 Crigler-Najjar syndrome type 1 CYP Cytochrome p450 DEX Dexamethasone EGF Epidermal growth factor fVII Factor VII FGF Fibroblast growth factor FHF Fulminant hepatic failure hAECs Hepatic differentiation of amniotic epithe…”
BackgroundInfluentialSelf-citationThomas, J. A., Pope, C., Wojtacha, D., Robson, A. J., Gordon-Walker, T. T., Hartland, S., Ramachandran, P., Van Deemter, M., Hume, D. A., Iredale, J. P., et al. (2011) · Hepatology · doi:10.1002/hep.24315 · Cited by 346
Human Hepatocytes with Drug Metabolic Function Induced from Fibroblasts by Lineage Reprogramming
Du, Y., Wang, J., Jia, J., Song, N., Xiang, C., Xu, J., Hou, Z., Su, X., Liu, B., Jiang, T., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.008 · Cited by 320 · cited 1×
“derived HLCs from human fibroblasts, with the generated hepatocytes possessing phase I/II/III drugmetabolic activity comparable to primary human hepatocytes [58].”
BackgroundIsolated Hepatocyte Transplantation in an Infant With a Severe Urea Cycle Disorder
Horslen, S. P., McCowan, T. C., Goertzen, T. C., Warkentin, P. I., Cai, H. B., Strom, S. C., & Fox, I. J. (2003) · Pediatrics · doi:10.1542/peds.111.6.1262 · Cited by 295
Cited by
Lin, F., Chen, W., Zhou, J., Zhu, J., Yao, Q., Feng, B., Feng, X., Shi, X., Pan, Q., Yu, J., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04708-w · Cited by 206
“5% of deaths worldwide result from liver diseases [3, 4].”
BackgroundMesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury
Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01895-1 · Cited by 130
Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Pinheiro, D., Dias, I., Ribeiro Silva, K., Stumbo, A. C., Thole, A., Cortez, E., de Carvalho, L., Weiskirchen, R., & Carvalho, S. (2019) · Cells · doi:10.3390/cells8111339 · Cited by 46
Metadata
- Authors
- Lee, C. A., Sinha, S., Fitzpatrick, E., & Dhawan, A.
- Venue
- Journal of Molecular Medicine
- Published
- 2018-04-24
- Volume
- 96
- Issue
- 6
- Pages
- 469-481
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2802916211
- Cited by
- 74
- References
- 14
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. https://app.cochat.ai/papers/10.1007/s00109-018-1638-5
- The paper
- Lee, C. A., Sinha, S., Fitzpatrick, E., & Dhawan, A. (2018). Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-018-1638-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.